Get the Stockscreener App
177.42
0.37%
0.65
Insmed Inc stock is traded at $177.42, with a volume of 747.29K.
It is up +0.37% in the last 24 hours and down -14.26% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$176.77
Open:
$175.5
24h Volume:
747.29K
Relative Volume:
0.27
Market Cap:
$37.84B
Revenue:
$447.02M
Net Income/Loss:
$-1.18B
P/E Ratio:
-28.70
EPS:
-6.1812
Net Cash Flow:
$-906.14M
1W Performance:
-10.60%
1M Performance:
-14.26%
6M Performance:
+67.54%
1Y Performance:
+151.55%
1-Day Range:
$175.00
$178.10
1-Week Range:
$161.02
$179.32
52-Week Range:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Finviz
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Insmed Incorporated (INSM) And Encourages Investors to Reach Out - ACCESS Newswire
Insmed sinks after brensocatib fails trial for sinus condition - MSN
Insmed stock plunges nearly 20% after hours as sinus drug fails mid-stage trial and shows no benefit - MSN
Pharmaceutical Stocks To ConsiderDecember 21st - MarketBeat
Why Insmed Incorporated stock is considered a top pickMarket Sentiment Extremes & Free Professional Investment Consultations - Bollywood Helpline
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Insmed Incorporated (INSM) And Encourages Stockholders to Reach Out - ACCESS Newswire
Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesday’s Open - ts2.tech
Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025) - ts2.tech
Insmed Incorporated(NasdaqGS: INSM) added to NASDAQ-100 Index - marketscreener.com
How analysts rate Insmed Incorporated stock today2025 Support & Resistance & Momentum Based Trading Ideas - Улправда
Insmed Earnings Notes - Trefis
What is HC Wainwright's Forecast for Insmed FY2025 Earnings? - MarketBeat
Insmed (INSM) Stock: What to Know Before the Market Opens on Dec. 22, 2025 - ts2.tech
Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025) - ts2.tech
Nike, Insmed, And Arm Are Among Top 10 Large Cap Losers Last Week (Dec. 15-Dec. 19): Are the Others in Your Portfolio?ARM Holdings (NASDAQ:ARM), BitMine Immersion (AMEX:BMNR), Insmed (NASDAQ:INSM), Lennar (NYSE:LEN) - Benzinga
INSM stock plummets on sinus study failure, adds new pipeline asset - MSN
Voya Investment Management LLC Sells 187,840 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed (BIT:1INSM) Price Target Increased by 16.99% to 218.23 - Nasdaq
The 'worst-case scenario' — why Insmed just reversed after a 181% six-month sprint - MSN
INSM Quantitative Stock Analysis - Nasdaq
Insmed Inc. buy Truist Financial Co. - sharewise.com
Truist Financial Upgrades Insmed (NASDAQ:INSM) to "Strong-Buy" - MarketBeat
Assenagon Asset Management S.A. Grows Position in Insmed, Inc. $INSM - MarketBeat
Will Insmed Incorporated (IM8N) stock announce a stock splitPortfolio Performance Summary & Accurate Intraday Trading Signals - ulpravda.ru
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO - RTTNews
What risks investors should watch in Insmed Incorporated stockWeekly Risk Summary & Stock Portfolio Risk Control - ulpravda.ru
Brinsupri setback slices Insmed market cap — Clinical Report - biocentury.com
Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 10,699 Shares of Stock - MarketBeat
Insmed Insider Sold Shares Worth $1,786,457, According to a Recent SEC Filing - marketscreener.com
INSMED Chair and CEO William Lewis Sells 10,699 Shares - TradingView — Track All Markets
Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next - ts2.tech
Insmed (MIL:1INSM) EV-to-FCF : -35.92 (As of Dec. 19, 2025) - GuruFocus
Insmed (MIL:1INSM) EV-to-OCF : -36.87 (As of Dec. 19, 2025) - GuruFocus
Will Insmed Incorporated (IM8N) stock test record highs in 2025July 2025 Macro Moves & Scalable Portfolio Growth Methods - DonanımHaber
Insmed Delivers ‘Rare Disappointment’ as Brinsupri Flops in Mid-Stage Rhinosinusitis Study - BioSpace
Goldman Sachs reiterates Buy rating on Insmed stock despite trial setback - Investing.com
FY2028 Earnings Estimate for Insmed Issued By HC Wainwright - MarketBeat
Is Insmed Incorporated stock a good choice for value investorsJuly 2025 Fed Impact & AI Enhanced Trading Signals - DonanımHaber
How Insmed Incorporated (IM8N) stock correlates with oil marketsBond Market & Real-Time Volume Analysis Alerts - Улправда
Truist Securities assumes coverage on Insmed stock with Buy rating By Investing.com - Investing.com Canada
Truist Securities assumes coverage on Insmed stock with Buy rating - Investing.com
How Insmed Incorporated stock performs in high volatility markets2025 Retail Activity & Technical Buy Zone Confirmation - DonanımHaber
Insmed Inc : Truist Securities Assumes Covera - 富途牛牛
Will Insmed Incorporated stock remain a Wall Street favoriteJuly 2025 Reactions & Weekly High Conviction Trade Ideas - Улправда
INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset - sharewise.com
Insmed stock price target lowered to $212 by Mizuho after negative study data - Investing.com Australia
RBC Capital Maintains Insmed (INSM) Outperform Recommendation - Nasdaq
HC Wainwright & Co. Maintains Insmed (INSM) Buy Recommendation - Nasdaq
Mizuho's Jared Holz talks Insmed sinking double digits on sinus drug trial news - CNBC
Chmn Lewis Files To Sell 10,699 Of Insmed Inc [INSM] - TradingView — Track All Markets
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):